688117.SH
圣诺生物
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 24.20
−6.17%Sep 3, 2026, 11:10 UTC
Shengnuo Biopharmaceutical's wholly-owned subsidiary Chengdu Shengnuo Biopharmaceutical received a drug registration certificate from China's National Medical Products Administration for linaclotide capsules (290μg), approving the product for market.
Source:Aug 28, 2026, 10:34 UTC
Sino Bio's wholly-owned subsidiary Chengdu Sino Bio Pharmaceutical received approval from China's National Medical Products Administration for the registration of its active pharmaceutical ingredient terlipressin acetate, packaged at 10g per bottle.
Source:Aug 19, 2026, 10:18 UTC
Shengnuo Biopharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 135 million yuan, up 51.98% year-on-year.
Source: